The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACST | -5.18% | N/A | N/A | -99% |
| S&P | +12.33% | +84.73% | +13.06% | +435% |
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Laval, Canada.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 100.0% |
| Market Cap | $41.17M | 0.0% |
| Market Cap / Employee | $10.29M | 0.0% |
| Employees | 4 | 0.0% |
| Net Income | -$0.94M | 72.7% |
| EBITDA | -$2.53M | 47.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $16.86M | 11.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -11.85% | 4.3% |
| Return On Invested Capital | -28.33% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.15M | 25.8% |
| Operating Free Cash Flow | -$3.15M | 25.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.68 | 0.44 | 0.61 | 0.65 | - |
| Price to Tangible Book Value | 5.52 | 8.05 | 2.35 | 2.88 | - |
| Enterprise Value to EBITDA | -8.64 | -2.87 | -8.84 | -12.08 | 201.44% |
| Return on Equity | -22.9% | -14.9% | -16.8% | -13.1% | -30.41% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
